Oncology

Latest News

No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.
Zurletrectinib Generates Responses in Advanced NTRK Fusion Solid Tumors

November 2nd 2025

No dose-limiting toxicities were observed in the phase 1/2 trial evaluating zurletrectinib in patients with NTRK/ROS1-driven malignancies.

Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome
Molecular Insights Into Cancer Cachexia: An Evolution in Identifying the Syndrome

November 2nd 2025

The denosumab-bmwo products Stoboclo and Osenvelt have been approved as interchangeable with the denosumab products Prolia and Xgeva, respectively.
FDA Grants Interchangeability Designation to 2 Denosumab Biosimilars

November 1st 2025

A unique cisplatin-containing intratumoral formulation achieved a median OS of 18.7 months in patients who were dosed at 40% or more of their TTB.
Novel Intratumoral Formulation Shows Responses/Safety in Metastatic Cancers

October 31st 2025

Latest CME Events & Activities

More News